A lot of companies in the medical sector have been spinning off divisions recently. Would that be a good move for conglomerate Johnson & Johnson too?
Our health care roundtable gathers the Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.
In this portion of the discussion, the Fool's health care team tackles the recent big pharma trend of spinning off whole divisions, like Abbott Labs' (ABT 0.44%) plans for pharmaceutical-focused AbbVie. Would conglomerate Johnson & Johnson (JNJ -0.08%) benefit from shedding a little extra weight and spinning off a company or two?
Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid.
The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
